Investigation to Understand and Optimize Psilocybin

Summary

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Eligibility

Inclusion Criteria:

Current diagnosis of Major Depressive Disorder (MDD), with a depressive episode lasting ≥ 60 consecutive days at the time of screening, as confirmed by structured clinical interview

Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.

Exclusion Criteria:

History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results (e.g., bipolar disorder, psychosis, seizure disorder, or cardiovascular disease).

Known family history of a psychotic disorder (e.g., schizophrenia or schizoaffective disorder) in a first-degree relative (biological parent, full sibling, or child).

Current active suicidal ideation with a specific plan within the prior 2 weeks, as assessed via clinical interview and validated instrument (e.g., C-SSRS).

Suicide attempt within the prior 6 months, regardless of intent or lethality.

Current diagnosis of a substance use disorder

Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).

Unwilling or unable to discontinue prescription psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, lithium, anticonvulsants, or mood stabilizers) for the duration of study participation, including any necessary washout period as determined by the investigator.

Any condition, finding, or behavior (including suspected deception or noncompliance) that, in the opinion of the investigator, renders the participant unsuitable for the study or likely to interfere with the integrity of the data or safety of the subject.

Conditions1

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Randomized Neuroimaging Trial of Psilocybin in Depression — Sunnybrook Health Sciences Centre
• Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression — University Health Network, Toronto
• PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL) — Ottawa Hospital Research Institute
• Psilocybin for Hospitalized Patients with Treatment-resistant Depression — University Hospital, Ghent
• Psilocybin for Treatment-Resistant Depression in Autism — Centre for Addiction and Mental Health
• Psilocybin Therapy for Depression in Parkinson's Disease — Joshua Woolley, MD, PhD
• Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence — University of Colorado, Denver
• Open-Label Psilocybin Study in Transdiagnostic Population — Yale University

Browse More Trials